​
Cardiometabolic disease is driven by inflammation, particularly in the adipose tissue. Inflammation consists of the initial acute phase, followed by a resolving phase. Importantly, the latter is regulated by specialized pro-resolving lipid mediators, e.g. the lipoxins, acting through defined receptors. 

​Our research focus on the investigation of specialized pro-resolving lipid mediators, such as the lipoxins, and their ability to promote cardiometabolic health in obesity.